Reza Elaidi

Reza Elaidi
Association Pour La Recherche Des Thérapeutiques Innovantes En Cancérologie · Department of Medical Oncology

About

75
Publications
3,667
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
1,260
Citations

Publications

Publications (75)
Preprint
Immune checkpoint inhibitors have revolutionized the treatment of patients with clear-cell renal carcinomas. Although, analyses of transcriptome, genetic alterations, and the tumor microenvironment have shed light into mechanisms of response and resistance to these agents, the role of epigenetic alterations in this process remains fully unknown. He...
Article
Background We previously reported a 35-gene expression classifier identifying four clear-cell renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments and sensitivities to sunitinib in metastatic clear-cell renal cell carcinoma. Efficacy profiles might differ with nivolumab and nivolumab–ipilimumab. We therefore aimed...
Article
The presence of intratumoral tertiary lymphoid structures (TLS) is associated with positive clinical outcomes and responses to immunotherapy in cancer. Here, we used spatial transcriptomics to examine the nature of B cell responses within TLS in renal cell carcinoma (RCC). B cells were enriched in TLS, and therein, we could identify all B cell matu...
Article
Full-text available
The development of antiangiogenic treatments, followed by immune checkpoint inhibitors (ICI), has significantly changed the management of metastatic clear cell renal cell cancer. Several phase III trials show the superiority of combination therapy, dual immunotherapy (ICI-ICI) or ICI plus tyrosine kinase inhibitors (TKI) of the vascular endothelium...
Article
Full-text available
Three drug combinations, ipilimumab-nivolumab (Ipi-Nivo), pembrolizumab-axitinib (Pembro-Axi), and avelumab-axitinib (Ave-Axi), have received regulatory approval in the USA and Europe for the treatment of metastatic renal cell carcinoma with clear cell component (mRCC). However, no head-to-head comparison data are available to identify the best opt...
Article
Background: Neoadjuvant cisplatin-based chemotherapy (NAC) is the standard of care in localized muscle-invasive bladder cancer (MIBC). However, 60-70% of patients have residual tumor after NAC. Based on the overall response rate observed in the metastatic setting, ddMVAC is the most commonly used NAC regimen in Europe. The emergence of immune check...
Article
Background: The nivolumab-ipilimumab combination provides an overall response rate of 42% in first-line metastatic treatment of clear cell renal carcinoma (mccRCC). To date, there is no robust predictive biomarker of response to immune checkpoint inhibitor (ICI). In addition, severe autoimmune disorders occur more frequently with ICI combination t...
Article
Résumé La prise en charge des carcinomes rénaux métastatiques à cellules claires (mccRCC) a considérablement évolué ces dernières années avec la multiplication des possibilités thérapeutiques : inhibiteurs de tyrosine kinase (ITK) du VEGFR, inhibiteurs de mTOR, inhibiteurs des points de contrôle du système immunitaire : anti-PD(L)-1 utilisés seuls...
Preprint
Background: Three drug-combinations, ipilimumab-nivolumab (Ipi-Nivo), pembrolizumab-axitinib (Pembro-Axi) and avelumab-axitinib (Ave-Axi), have received regulatory approvals in USA and Europe for the treatment of metastatic renal cell carcinoma with clear cell component (mRCC). However, no head-to-head comparison data are available to identify the...
Article
Introduction: Recent trials have suggested predictive biomarkers in advanced clear-cell renal cell carcinoma (accRCC): International Metastatic RCC Database Consortium (IMDC) good risk or angiogenic gene signature for sunitinib and IMDC intermediate/poor risk for ipilimumab-nivolumab and T-effector cell signature or sarcomatoid dedifferentiation f...
Article
Full-text available
Importance: Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-risk prostate cancer setting. Objective: To assess the benefit of ADT plus docetaxel in patients presenting with rising prostate-specific antigen (PSA) levels after...
Article
INTRODUCTION. Crotoxin is a bipartite South America rattle snake neurotoxin. It has broad spectrum antitumor activity in addition to exerting analgesic effects. Prior clinical reports using i.m. injections resulted in local immune reactions with erythema, itching or pain, in addition to anaphylaxis though encouraging responses were recorded. A clin...
Article
Full-text available
This study assessed the prognostic value of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic solid tumors. Clinical and biological data for patients with metastatic solid tumors treated in an oncology outpatient department and prospectively followed by a call center (PROCHE program) between January 2008 and December 20...
Data
Hazard rate for death by tumor type. H&N, head and neck. (DOCX)
Data
Time-varying value of the neutrophil-to-lymphocyte ratio (NLR) effect in the Cox model. (DOCX)
Data
Multivariate analysis of effect of continuous and categorised neutrophil-to-lymphocyte ratio values (cut-off 3.0 and 4.0) in patients receiving first-line chemotherapy (cohort 1, n = 317). (DOCX)
Data
Adjusted Kaplan-Meier curves for the relationship between the neutrophil-to-lymphocyte ratio (NLR) as a categorical variable and overall survival (OS) in cohort 1 (n = 317) for NLR cut-off values of 3 (A) and 4 (B). Adjustment was made for age, gender, disease site, and Eastern Co-operative Oncology Group performance status. CI, confidence interval...
Article
Full-text available
This report aims to review criteria which have been proposed for treatment evaluation in mRCC under anti-angiogenic and immune-oncologic therapies and discuss future challenges for imagers. RECIST criteria seem to only partially reflect the clinical benefit derived from anti-angiogenic drugs in mRCC. New methods of analysis propose to better evalua...
Article
Full-text available
Introduction: Crotoxin has a broad antitumor activity but has shown frequent neurotoxic toxicity. To induce tolerance and limit this toxicity, we propose a new design with intra-patient dose escalation. Methods: A new Dose Limiting Toxicity definition was used. The concept of Target Ceiling Dose was introduced. Results: Dose Limiting Toxicity was t...
Article
10120 Background: The PROCHE [Programme for optimisation of the chemotherapy network] initiative is an innovative oncology-monitoring program designed to reduce patient waiting time and chemotherapy wastage, ultimately improving patient care. Methods: Primary objective was to evaluate the incidence of nausea reported by grade (NCI-CTC AE: from 0 to...
Article
Background: The objective of the study was to assess the prognostic role of skeletal muscle index (SMI) in metastatic renal cell carcinoma (mRCC) patients treated with everolimus, and its effect of on everolimus-induced toxicity. Patients and methods: Consecutive mRCC patients treated with everolimus between February 2007 and November 2014 under...
Article
Full-text available
Background Metabolic toxicities of mTOR inhibitors (mTORi) are well characterized. The purpose of the study was to investigate the relationship between these metabolic toxicities and mTORi efficacy. Methods From 2007 to 2011, metabolic toxicities were retrospectively collected in patients treated with an mTORi (everolimus, temsirolimus) for a meta...
Article
Full-text available
Von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary cancer syndrome that predisposes affected individuals to the development of multiple benign and malignant tumors. One of the main manifestations of VHL is renal cell carcinoma (RCC). RCC is increasingly being treated with targeted therapies, which offer an alternative treatment opt...
Article
Background: A high neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation and is associated with poor survival in localized or metastatic cancer. This study assessed the prognostic value of NLR after first-line chemotherapy (CT) in patients with metastatic urothelial carcinoma (mUC). Patients and methods: Two hundred eighty co...
Article
Objectives: To validate vascular endothelial growth factor receptor-1 (VEGFR1) single nucleotide polymorphism (SNP) rs9582036 as a potential predictive biomarker in metastatic clear-cell renal cell carcinoma (m-ccRCC) patients treated with sunitinib. Materials and methods: m-ccRCC patients receiving sunitinib as first-line targeted therapy were...
Chapter
Brain metastases occur in 20–40% of cancers. Intracranial bleeding is one of the fatal complications encountered in this context. Primitive tumor is mainly located in lung (40%), breast (17%), melanoma (10%), and kidney or bladder (6%). Increased incidence could be explained by (1) treatment’s resistance by clonal escape, (2) improvements in diagno...
Article
Full-text available
Background: Bone metastases (BMs) are associated with poor outcome in metastatic clear-cell renal carcinoma (m-ccRCC) treated with anti-vascular endothelial growth factor tyrosine kinase inhibitors (anti-VEGFR-TKIs). We aimed to investigate whether expression in the primary tumour of genes involved in the development of BM is associated with outco...
Article
To determine whether 2D or 3D Choi and modified Choi (mChoi) criteria could assess the efficacy of everolimus against metastatic renal cell carcinoma (mRCC). RECIST-1.1, Choi, and mChoi criteria were applied retrospectively to analyse baseline and 2-month contrast-enhanced computed tomography (CECT) images in 48 patients with mRCC enrolled in the e...
Article
Purpose: Selecting patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) who might benefit from treatment with targeted tyrosine kinase inhibitors (TKIs) is a challenge. Our aim was to identify molecular markers associated with outcome in m-ccRCC patients treated with sunitinib. Experimental Design: We performed global transcriptome an...
Article
Full-text available
Background Although sequential targeted therapy is standard in patients with metastatic clear-cell renal cell carcinoma (m-ccRCC), the choice of drugs and optimal administration sequence have yet to be established. The objective of this study was to explore whether it is preferable to rechallenge a long-term responder to a first-line tyrosine kinas...
Article
Objective To evaluate the prognostic role of cytoreductive nephrectomy (CN) in patients with metastatic RCC (mRCC) and synchronous metastases, treated with the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) sunitinib. Patients and Methods Patients with a diagnosis of metastases prior to, at the time of or withi...
Conference Paper
Aim: A Cis-based CT has become a standard in first-line for mUC in fit pts, whereas a Ca-based CT is usually preferred in unfit pts. A significant advantage of Cis-based CT on objective response had previously been observed in a meta-analysis (Galsky, 2012), but survival endpoints could not be assessed. Methods: Clinical, biological, radiological d...
Article
Full-text available
Aim: Pre-treatment Neutrophil to Lymphocyte Ratio (NLR), an index of systemic inflammation, has been reported as a prognostic factor in some metastatic solid tumors (mST). Whether the NLR prognostic value depends on primary tumor site (PTS) has never been investigated. This study aimed to assess the prognostic value of pre-treatment NLR in pts with...
Article
Full-text available
Aim: Sarcopenia defined by a low SMI, has been identified as a prognostic factor in mRCC patients (pts) treated with tyrosine kinase inhibitors. Everolimus (Ev) has been approved in second- and third-line for mRCC. This study aimed to assess the prognostic role of SMI in mRCC pts treated with everolimus. Methods: Consecutive mRCC pts treated with E...
Article
Full-text available
Aim: Fatigue (F) and anemia (A) are common adverse reactions in patients (pts) treated with chemotherapy. The relationship between fatigue and anemia is complex and still unexplained. This study aimed to investigate the time dependant relationship between hemoglobin (Hb) levels and patient's reported fatigue. Methods: Patients (pts) included in the...
Article
Full-text available
Aim: The PROCHE [Programme for optimisation of the chemotherapy network] initiative is an innovative oncology-monitoring program designed to reduce patient waiting time and chemotherapy wastage, ultimately improving patient care. Laboratory test results and side effects data are collected for patients in the PROCHE monitoring program 2 days prior t...
Article
Full-text available
Purpose: We conducted a phase I multicenter trial in naïve metastatic castrate-resistant prostate cancer patients with escalating inecalcitol dosages, combined with docetaxel-based chemotherapy. Inecalcitol is a novel vitamin D receptor agonist with higher antiproliferative effects and a 100-fold lower hypercalcemic activity than calcitriol. Expe...
Article
A prostate-specific antigen (PSA) flare occurs in about 15% of metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel. This flare has no standard definition. Its impact on treatment efficacy is unclear. We sought to evaluate the incidence and characteristics of PSA flare on cabazitaxel, and its impact on survival. Mult...
Article
282 Background: Early CRPC (<12 months, m) with 1st hormonal therapy (HT) was found to predict poor efficacy of 2nd HT, but did not seem to impair the benefit of D-based chemotherapy. We evaluated the impact of this variable in our cohort of patients (pts) treated also with second-line chemotherapy C. Methods: Records of 132 consecutive mCRPC pts w...
Article
Full-text available
The aim of this study was to assess the treatment patterns and safety of sunitinib, sorafenib and bevacizumab in real-world clinical settings in US, Europe and Asia. Medical records were abstracted at 18 community oncology clinics in the US and at 21 tertiary oncology centers in US, Europe and Asia for 883 patients ≥18 years who had histologically/...
Article
Full-text available
Background: Accurate prediction of outcome for metastatic renal cell carcinoma (mRCC) patients receiving targeted therapy is essential. Most of the available models have been developed in patients treated with cytokines, while most of them are fairly complex, including at least five factors. We developed and externally validated a simple model for...
Article
Objective: To determine if mammalian target of rapamycin (mTOR) inhibitor (everolimus or temsirolimus) rechallenge in the third- or fourth-line setting after sequential use of a vascular endothelial growth factor receptor (VEGF)-targeted agent and an mTOR inhibitor is a feasible and effective treatment strategy in patients with metastatic renal ce...
Article
Full-text available
Background: There are no validated markers that predict outcome in metastatic renal cell cancer (mRCC) patients treated with sunitinib. Recently, single nucleotide polymorphism (SNP) rs9582036 in VEGFR1 has been proposed as a predictor of progression-free survival (PFS) and overall survival (OS) to bevacizumab in patients with pancreatic cancer an...
Article
122 Background: PSA initial flare followed by a decrease is documented in up to 18% of mCRPC patients (pts) treated with docetaxel (D). There is no standard definition of this phenomenon, and its significance in terms of treatment efficacy and prognosis remains unclear. We evaluated the PSA flare incidence and characteristics with cabazitaxel (C),...
Article
137 Background: Potential predictors of low response to 2d HT including new agents have been recently identified: high Gleason score, rapid progression with first androgen deprivation therapy (ADT), chemotherapy lines >1 and low baseline testosterone (T) levels. We evaluated the influence of these factors on the efficacy of cabazitaxel (C), a new t...
Conference Paper
PURPOSE We studied whether CHOI and modified CHOI (mCHOI) criterion might be valuable to assess everolimus efficacy. METHOD AND MATERIALS We, retrospectively, reviewed the computed tomography (CT) of 105 mRCC patient enrolled in the French centers that participated to the randomized, double-blind, multicenter phase III study comparing Everolimus v...
Article
Full-text available
Background: The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase inhibitors (TKIs) is associated with poorer outcome as compared with patients without bone involvement. Concomitant bisphosphonates could probably improve outcomes but also induce osteonecrosis of the jaw (ONJ). Methods: R...
Article
The PROCHE (PRogramme d'Optimisation du circuit CHimiothErapie [Programme for optimisation of the chemotherapy network]) initiative is an innovative oncology-monitoring program designed to reduce patient waiting time and chemotherapy wastage, ultimately improving patient care. Laboratory test results and side effects data were collected for patient...
Article
Prognosis of patients with renal carcinoma has improved since the advent of targeted therapies. These last years, due to the improvement of patients overall survival, the incidence of brain metastasis among renal carcinoma patients has increased. This worsens the prognosis of patients. The present revue aims to do a point on treatment of brain meta...
Article
375 Background: The question regarding the benefit of a TKI rechallenge versus switch to an mTOR inhibitor (mTORi) in mRCC pts who responded to a previous line of TKI remains unanswered and is a common dilemma in clinical practice. We report results of a retrospective study to address this question. Methods: This study retrospectively investigated...
Article
442 Background: question regarding the benefit of a mTORi re-challenge for pts treated with a previous line of TKI and 1 line of mTORi remains unanswered in mRCC. Methods: this study retrospectively investigated Treatment Duration (TD), best overall response (OR) in pts treated with TKI and mTORi in a sequence temsirolimus-everolimus (T-E) or evero...
Article
Multiple targeted agents are now available for the treatment of patients with metastatic renal cell carcinoma (mRCC). Although targeted agents offer improvements over previous treatments and significantly prolong progression-free survival, most patients eventually experience disease progression. For these patients, sequential treatment with multipl...
Article
Résumé Les tumeurs du rein se positionnent au septième rang de fréquence des cancers de l'homme en Europe. Il s'agit des tumeurs rares dans 10 à 15 % des cas. Les carcinomes des canaux collecteurs du rein ou tumeur de Bellini, décrits pour la première fois en 1949, en sont une entité anatomoclinique distincte et représentent environ 1 % des cancers...
Article
The aim of our study was to determine whether the presence of bone metastases affects outcomes in patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) receiving sunitinib. We reviewed the charts of all patients in four academic centers in Belgium and France who started first-line sunitinib (50 mg/day; 4 weeks on and 2 weeks off) betwe...
Article
Résumé Le cancer du rein représente actuellement 3 % de l’ensemble des cancers. L’utilisation de cytokines dans le stade métastatique de la maladie a été le standard jusqu’à ces dernières années, produisant des réponses partielles et de courtes durées. La recherche sur l’angiogenèse dans le cancer du rein a entraîné des avancées considérables pour...
Article
The recent introduction of drugs that inhibit angiogenesis or the mTOR has provided new options for the treatment of metastatic renal cell carcinoma, a disease which often has a poor prognosis. Chemotherapy and cytokine therapy are largely ineffective. The 5-year survival rate is under 10%. Everolimus, an immunosuppressive drug widely used for the...

Network